,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,330,1,1,,145094,68148,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
1,166551,3,4,,103330683,68148,Unspecified,,,,,Percentage inhibition against release of beta-hexosaminidase from RBL-2H3 cells at 100 uM from control,Other,12951092.0,
2,247905,6,2,,103330683,68148,Unspecified,,,200.0,IC50,Cytotoxicity of compound against human liver tumor cell line (Hep-G2) was determined,Confirmatory,15582432.0,
3,248765,9,1,,103330683,68148,Unspecified,,,100.0,IC50,Inhibitory concentration of compound on nitric oxide (NO) production in lipopolysaccharide activated mouse peritoneal macrophages,Confirmatory,15780639.0,
4,252044,3,3,,103330683,68148,Unspecified,,,,,Percent inhibition of nitric oxide (NO) production in lipopolysaccharide activated mouse peritoneal macrophages at 100 uM of compound,Other,15780639.0,
5,1110759,3,1,,103330683,68148,Unspecified,,,,,Nematocidal activity against Caenorhabditis elegans assessed as mortality,Other,12147760.0,
6,1259407,1,1,,363901158,68148,Inactive,,,,,CCRIS mutagenicity studies,Other,,
